Dengue: A Minireview

Harapan, Harapan; Michie, Alice; Sasmono, R. Tedjo; Imrie, Allison

doi:10.3390/v12080829

Cited by 189 publications

(261 citation statements)

References 268 publications

(398 reference statements)

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…In some cases, other neurological manifestations such as headache, dizziness, seizure, taste and smell impairment were also reported 12,[18][19][20][21] . Headache is one of the symptoms that is also reported in various viral infections such as dengue and chikungunya that are common in the tropical regions 22,23 and therefore may not be specific for COVID -19. In addition, the prevalence of headache in COVID-19 patients varies across studies 19,20,24 . A study found that the prevalence of headache was 17.4% (94/540) in Hubei province, the epicenter of the outbreak, and 14.1% (111/788) among patients outside the epicenter 21 .…”

Section: Introductionmentioning

confidence: 99%

Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: This study was conducted to determine the prevalence of headache in coronavirus disease 2019 (COVID-19) and to assess its association as a predictor for COVID-19. This study also aimed to discuss the possible pathogenesis of headache in COVID-19. Methods: Available articles from PubMed, Scopus, and Web of Science were searched as of September 2nd, 2020. Data on characteristics of the study, headache and COVID-19 were extracted following the PRISMA guidelines. Biases were assessed using the Newcastle-Ottawa scale. The cumulative prevalence of headache was calculated for the general population (i.e. adults and children). The pooled odd ratio (OR) with 95% confidence intervals (95%CI) was calculated using the Z test to assess the association between headache and the presence of COVID-19 cases. Results: We included 104,751 COVID-19 cases from 78 eligible studies to calculate the global prevalence of headache in COVID-19 and 17 studies were included to calculate the association of headache and COVID-19. The cumulative prevalence of headache in COVID-19 was 25.2% (26,464 out of 104,751 cases). Headache was found to be more prevalent, approximately by two-fold, in COVID-19 patients than in non-COVID-19 patients (other respiratory viral infections), OR: 1.73; 95% CI: 1.94, 2.5 with p=0.04. Conclusion: Headache is common among COVID-19 patients and seems to be more common in COVID-19 patients compared to those with the non-COVID-19 viral infection. No definitive mechanisms on how headache emerges in COVID-19 patients but several possible hypotheses have been proposed. However, extensive studies are warranted to elucidate the mechanisms. PROSPERO registration: CRD42020210332 (28/09/2020)

show abstract

Section: Introductionmentioning

confidence: 99%

Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dengue is a mosquito-borne viral disease caused by infection with any of four dengue virus (DENV) serotypes (DENV-1 to DENV-4). 1 With an estimated 390 million annual infections in 2010, of which 96 million with clinical manifestations, dengue is a major public health burden, notably in tropical and sub-tropical regions of the world. 2,3 Its incidence dramatically increased in the last 50 years in these regions and has recently begun to increase in Europe.…”

Section: Introductionmentioning

confidence: 99%

“…1,3,4 Dengue is a systemic and progressive disease with symptoms ranging from mild to severe. 1,3 Following an early febrile phase that lasts for 2 to 7 days, patients enter a critical phase during which patients’ condition either improves or worsens, and may evolve into life-threatening severe dengue, with a potentially fatal outcome. 1,3 DENV serotype and secondary infection are among the factors associated with disease severity.…”

Section: Introductionmentioning

confidence: 99%

“…1 If the patient survives the first 24-48-hour critical phase, the final recovery phase will take its course over the following 48-72 hours. 1,3 No specific therapy against dengue exist but patient management protocols have been implemented to limit severe dengue complications. 1,3 The first licensed dengue vaccine is restricted to people aged 9-45 years and is only recommended for those with evidence of a past dengue infection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of VIDAS® diagnostic assay prototypes detecting dengue virus NS1 antigen and anti-dengue virus IgM and IgG antibodies

Somlor¹,

Brossault

Grandadam³

2021

Preprint

View full text Add to dashboard Cite

Dengue is a tropical disease caused by the mosquito-borne dengue virus (DENV) and affecting an estimated 96 million people each year. Performant, rapid and easy-to-use assays are needed for the accurate diagnosis of acute DENV infection. This study evaluated the performance of three prototype assays developed for the VIDAS automated platform to detect dengue NS1 antigen and anti-dengue IgM and IgG antibodies. Positive and negative agreement with competitor enzyme-linked immunosorbent assays (ELISA) and rapid diagnostic tests (RDT) was evaluated in 91 Lao patients (57 adults, 34 children) with acute DENV infection. The VIDAS NS1 assay showed the best overall agreement (95.6%; 95% confidence interval [CI]: 89.1-98.8%) with the competitor NS1 ELISA (Focus Diagnostics). Both assays also demonstrated high sensitivity relative to DENV RNA real time RT-PCR set as gold standard (85.7% [95% CI: 74.3-92.6%] and 83.9% [95% CI: 72.2-91.3%], respectively). Concordance of the VIDAS results was overall higher with the competitor ELISA than with the RDT, suggesting a better performance of VIDAS assays over RDT. The overall agreement of VIDAS IgM and IgG assays with the competitor ELISA (Panbio/Abbott) was moderate (72.5%, 95% CI [62.6-80.6%] for IgM; 76.9%, 95% CI [67.3-84.4%] for IgG), highlighting differences in sensitivity and/or specificity between these assays. In all comparisons, test agreements did not differ significantly between adults and children, indicating comparable performance of the VIDAS assays in both populations. Altogether, the VIDAS dengue prototypes performed very well and appear to be suitable for routine detection of dengue NS1 antigen and anti-dengue IgM/IgG antibodies.

show abstract

“…Moreover, ZIKV infection is a major threat during pregnancy, as the virus can be transmitted vertically and cause microcephaly [25,26]. DENV followed a similar spread-scheme as ZIKV [27]. Its first identification dates back to 1943 in Japan [28,29].…”

Section: Flaviviruses' Outbreaksmentioning

confidence: 99%

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge

et al. 2020

View full text Add to dashboard Cite

The RNA-dependent RNA polymerase (RdRp) is an essential enzyme for the viral replication process, catalyzing the viral RNA synthesis using a metal ion-dependent mechanism. In recent years, RdRp has emerged as an optimal target for the development of antiviral drugs, as demonstrated by recent approvals of sofosbuvir and remdesivir against Hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respectively. In this work, we overview the main sequence and structural features of the RdRp of emerging RNA viruses such as Coronaviruses, Flaviviruses, and HCV, as well as inhibition strategies implemented so far. While analyzing the structural information available on the RdRp of emerging RNA viruses, we provide examples of success stories such as for HCV and SARS-CoV-2. In contrast, Flaviviruses’ story has raised attention about how the lack of structural details on catalytically-competent or ligand-bound RdRp strongly hampers the application of structure-based drug design, either in repurposing and conventional approaches.

show abstract

Dengue: A Minireview

Cited by 189 publications

References 268 publications

Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis

Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis

Evaluation of VIDAS® diagnostic assay prototypes detecting dengue virus NS1 antigen and anti-dengue virus IgM and IgG antibodies

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge

Contact Info

Product

Resources

About